Drugs that contain Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate
1. List of Mydayis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6913768 | TAKEDA PHARMS USA | Sustained release delivery of amphetamine salts |
May, 2023
(3 months from now) | |
| US9173857 | TAKEDA PHARMS USA | Controlled dose drug delivery system |
May, 2026
(3 years from now) | |
| US8846100 | TAKEDA PHARMS USA | Controlled dose drug delivery system |
Aug, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Sep 13, 2022 |
| Pediatric Exclusivity (PED) | Mar 13, 2023 |
Market Authorisation Date: 20 June, 2017
Treatment: Treatment of attention deficit hyperactivity disorder
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of MYDAYIS before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic